Successful IPO for CF PharmTech

karo IP supports IPO with IP expertise

On October 8, 2025, one of our clients, the pharmaceutical company CF PharmTech (headquartered in Suzhou, China), successfully completed its listing on the Hong Kong Stock Exchange (HKSE).

Our client is a fully integrated pharmaceutical company focused on the research, development, manufacturing, and marketing of drugs and devices for the treatment of respiratory diseases. The company’s core product is Budesonide Suspension (CF017), a drug for the treatment of asthma and COPD that is included in China’s volume-based procurement program. In addition, the company has other products and a pipeline of innovative therapies, including RNAi therapies and small molecule drugs.

The IPO was heavily oversubscribed and the share price rose significantly on the first day of trading, reflecting strong investor interest in the company’s focus on the treatment of respiratory diseases and its path to profitability.

We are very pleased to have been asked to support our client’s IPO with various searches, valuations and opinions on patents, utility models and trademarks in the European territories, thus contributing to the successful IPO of CF PharmTech and its further successful path on the European market.